Leonard G. Gomella, MD, FACS, led a panel discussion on “Next Generation Genomics and Prostate Cancer Biomarkers” virtually during the 21st Annual Future Directions in Urology Symposium in August 2020.

How to cite: Gomella, Leonard G. Panel Discussion: Next Generation Genomics and Prostate Cancer Biomarkers” August 10th, 2020. Accessed Oct 2020. https://grandroundsinurology.com/panel-discussion-next-generation-genomics-and-prostate-cancer-biomarkers/

Summary:

Leonard G. Gomella, MD, FACS, leads a panel discussion with Gerald L. Andriole, Jr., MD; Alan H. Bryce, MD; Brian F Chapin, MD; E. David Crawford, MD; Steven E. Finkelstein, MD, FACRO; A. Karim Kader, MD, PhD; and Neal D. Shore, MD, FACS on how biomarkers are being used to treat prostate cancer.  Biomarkers are used to diagnose PCa and to decide whether or not to biopsy or repeat biopsy.  They also discuss how biomarkers are used to treat localized disease and advanced disease.  Both tissue and liquid biopsies are used for somatic DNA mutations, with liquid biopsies becoming increasingly important since it gives real-time results.  Guidelines for germline testing and counseling are being updated, and germline testing for family members is becoming increasingly important.  PARP inhibitors are now approved for detecting BRCA mutations.  There is broader approval for the medication olaparib for both germline and somatic testing.  They also review the updated biomarker map.  They discuss how these changes will shape precision medicine and personalized care.  It is essential for the urology community to be familiar with all these aspects of testing and clinical applications. They discuss why the PCA 3 test has been declining.  They also discuss the need to send a clear message to primary care physicians.

About The 2020 Virtual Future Directions in Urology Symposium
The Future Directions in Urology Symposium was founded 21 years ago to reflect on the current state of the urology community and predict trends in the treatment of urology conditions in the following 5-10 years. This conference brings together experts in the field, including urologists, medical oncologists, radiation oncologists, family practice doctors, researchers, and industry leaders to review current trends and prospects. Dr. Gomella led this panel discussion during this year’s virtual conference in August 2020.